A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Biopsy-confirmed diagnosis of CD for at least 3 months prior to Baseline.
Participant meets the following disease activity criteria:
1. Moderate to severe CD as assessed by CDAI
2. Endoscopic evidence of mucosal inflammation as documented by a SES-CD
Participant has demonstrated intolerance, loss of response or inadequate response to conventional or advanced therapies for CD.
You may not be if
Participants with a current diagnosis of ulcerative colitis or indeterminate colitis.
Participants with unstable doses of concomitant Crohn's disease therapy.
Participants with prior exposure to p19 inhibitors.
Participants with complications of Crohn's disease.
Participants having an ostomy or ileoanal pouch.
Clareo Health | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
